BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
- 1 October 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 6 (10) , 1234-1245
Abstract
KRAS mutation is present in approximately 30% of human lung adenocarcinomas. Although recent advances in targeted therapy have shown great promise, effective targeting of KRAS remains elusive, and concurrent alterations in tumor suppressors render KRAS-mutant tumors even more resistant to existing therapies. Contributing to the refractoriness of KRAS-mutant tumors are immunosuppressive mechanisms, such as increased presence of suppressive regulatory T cells (Treg) in tumors and elevated expression of the inhibitory receptor PD-1 on tumor-infiltrating T cells. Treatment with BET bromodomain inhibitors is beneficial for hematologic malignancies, and they have Treg-disruptive effects in a non–small cell lung cancer (NSCLC) model. Targeting PD-1–inhibitory signals through PD-1 antibody blockade also has substantial therapeutic impact in lung cancer, although these outcomes are limited to a minority of patients. We hypothesized that the BET bromodomain inhibitor JQ1 would synergize with PD-1 blockade to promote a robust antitumor response in lung cancer. In the present study, using Kras+/LSL-G12D; Trp53L/L (KP) mouse models of NSCLC, we identified cooperative effects between JQ1 and PD-1 antibody. The numbers of tumor-infiltrating Tregs were reduced and activation of tumor-infiltrating T cells, which had a T-helper type 1 (Th1) cytokine profile, was enhanced, underlying their improved effector function. Furthermore, lung tumor–bearing mice treated with this combination showed robust and long-lasting antitumor responses compared with either agent alone, culminating in substantial improvement in the overall survival of treated mice. Thus, combining BET bromodomain inhibition with immune checkpoint blockade offers a promising therapeutic approach for solid malignancies such as lung adenocarcinoma. Cancer Immunol Res; 6(10); 1234–45. ©2018 AACR.Keywords
All Related Versions
Funding Information
- NCI (R01 CA216188, CA205150, CA166480, CA213333, CA098101, and CA154303)
This publication has 49 references indexed in Scilit:
- Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung CancerCancer Discovery, 2017
- Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse modelProceedings of the National Academy of Sciences, 2016
- The Basis of OncoimmunologyCell, 2016
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative PotentialCell, 2015
- Functional dynamics of Foxp3+ regulatory T cells in mice and humansImmunological Reviews, 2014
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung TumorsCancer Discovery, 2013
- Microenvironmental regulation of tumor progression and metastasisNature Medicine, 2013
- Cytokines and the inception of CD8 T cell responsesTrends in Immunology, 2011
- CD28 and CTLA‐4 coreceptor expression and signal transductionImmunological Reviews, 2009
- The tumor microenvironment and its role in promoting tumor growthOncogene, 2008